Perphenazine and Perphenazine Decanoate

Jonathan M. Meyer; Stephen M. Stahl

doi:10.1017/9781009002103.012

9 - Perphenazine and Perphenazine Decanoate

Published online by Cambridge University Press: 19 October 2021

Jonathan M. Meyer and

Stephen M. Stahl

Show author details

Jonathan M. Meyer: Affiliation:
University of California, San Diego
Stephen M. Stahl: Affiliation:
University of California, Riverside and San Diego

Book contents

Get access

Summary

As with many first-generation antipsychotics (FGAs), perphenazine has no unique therapeutic benefit compared to other D2 antagonists, but does have a long-acting injectable (LAI) preparation available in certain parts of the world (Belgium, Denmark, Finland, Iceland, The Netherlands, Norway, Portugal, Sweden) and a large database of plasma level information. As the FGA arm of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, many clinicians came to appreciate that modest perphenazine dosages are effective, that perphenazine is associated with lower metabolic risk than many second-generation antipsychotics, and that perphenazine treatment is associated with less prolactin elevation than risperidone therapy [2, 3].

Type: Chapter
Information: The Clinical Use of Antipsychotic Plasma Levels
Stahl's Handbooks
, pp. 190 - 200

DOI: https://doi.org/10.1017/9781009002103.012 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Linnet, K. and Wiborg, O. (1996). Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther, 60, 41–47.Google Scholar

Lieberman, J. A., Stroup, T. S., McEvoy, J. P., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 353, 1209–1223.Google Scholar

Meyer, J. M., Davis, V. G., Goff, D. C., et al. (2008). Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res, 101, 273–286.Google Scholar

Sweet, R. A., Pollock, B. G., Mulsant, B. H., et al. (2000). Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol, 20, 181–187.Google Scholar

Jin, Y., Pollock, B. G., Coley, K., et al. (2010). Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. J Clin Pharmacol, 50, 73–80.Google Scholar

Hansen, L. B. and Larsen, N. E. (1985). Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berl), 87, 16–19.Google Scholar

Mazure, C. M., Nelson, J. C., Jatlow, P. I., et al. (1990). The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. J Clin Psychiatry, 51, 330–334.Google Scholar

Kistrup, K., Gerlach, J., Aaes-Jorgensen, T., et al. (1991). Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients: serum levels at the minimum effective dose. Psychopharmacology, 105, 42–48.Google Scholar

Talvik, M., Nordstrom, A. L., Larsen, N. E., et al. (2004). A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology, 175, 148–153.Google Scholar

Schoretsanitis, G., Kane, J. M., Correll, C. U., et al. (2020). Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology (ASCP) and the Therapeutic Drug Monitoring (TDM) Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP). J Clin Psychiatry, 81, https://doi.org/10.4088/JCP.4019cs13169.Google Scholar

Mylan Pharmaceuticals Inc. (2018). Perphenazine package insert. Morgantown, WV.Google Scholar

Patteet, L., Morrens, M., Maudens, K. E., et al. (2012). Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit, 34, 629–651.Google Scholar

Olesen, O. V. and Linnet, K. (2000). Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol, 50, 563–571.Google Scholar

Dahl-Puustinen, M. L., Liden, A., Alm, C., et al. (1989). Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther, 46, 78–81.Google Scholar

Ozdemir, V., Naranjo, C. A., Herrmann, N., et al. (1997). Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther, 62, 334–347.Google Scholar

Mulsant, B. H., Foglia, J. P., Sweet, R. A., et al. (1997). The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol, 17, 318–321.Google Scholar

Halayqa, M. and Domanska, U. (2014). PLGA biodegradable nanoparticles containing perphenazine or chlorpromazine hydrochloride: effect of formulation and release. Int J Mol Sci, 15, 23909–23923.Google Scholar

Taylor, D. (2009). Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review. Br J Psychiatry Suppl, 52, S13–19.Google Scholar

Knudsen, P., Hansen, L. B., Auken, G., et al. (1985). Perphenazine decanoate vs. perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand Suppl, 322, 15–28.Google Scholar

Tuninger, E. and Levander, S. (1997). Long-term outcome of depot neuroleptic maintenance treatment among chronic psychotic patients. Acta Psychiatr Scand, 96, 347–353.Google Scholar

Meyer, J. M. (2017). Converting oral to long acting injectable antipsychotics: a guide for the perplexed. CNS Spectr, 22, 14–28.Google Scholar

Orion Pharma AB (2017). Trilafon Dekanoat. Danderyd, Sweden.Google Scholar

Larsen, N. E. and Hansen, L. B. (1989). Prediction of the optimal perphenazine decanoate dose based on blood samples drawn within the first three weeks. Ther Drug Monit, 11, 642–646.Google Scholar

Dencker, S. J., Giös, I., Mårtensson, E., et al. (1994). A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology (Berl), 114, 24–30.Google Scholar

Marder, S. R., Midha, K. K., Van Putten, T., et al. (1991). Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry, 158, 658–665.Google Scholar

Haddad, P., Lambert, T., and Lauriello, J., eds. (2016). Antipsychotic Long-Acting Injections, 2nd edn. New York: Oxford University Press.Google Scholar

Eggert Hansen, C., Rosted Christensen, T., Elley, J., et al. (1976). Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol, 3, 915–923.Google Scholar

Hansen, L. B. and Larsen, N. E. (1977). Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology, 53, 127–130.Google Scholar

Hansen, L. B., Larsen, N. E., and Gulmann, N. (1982). Dose–response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berl), 78, 112–115.Google Scholar

Van Putten, T., Marder, S. R., Mintz, J., et al. (1992). Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am J Psychiatry, 149, 500–505.Google Scholar

Midha, K. K., Hubbard, J. W., Marder, S. R., et al. (1994). Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci, 19, 254–264.Google Scholar

Regenthal, R., Kunstler, U., Junhold, U., et al. (1997). Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Int Clin Psychopharmacol, 12, 255–261.Google Scholar

Simpson, G. M. and Kunz-Bartholini, E. (1968). Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv System, 29, 269–274.Google Scholar